Trial reportDementia and geriatric cognitive disorders2009
Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease.
Trial report in Dementia and geriatric cognitive disorders, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 46 citations in OpenAlex.
- Article
- Comparative Study of Ex Vivo Transmucosal Permeation of Pioglitazone Nanoparticles for the Treatment of Alzheimer's Disease.Polymers · 2018Article
- Cilostazol as an add-on therapy for patients with Alzheimer's disease in Taiwan: a case control study.BMC neurology · 2017Article
- Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer's disease.Psychopharmacology · 2013Article
- Progress in frontotemporal dementia research.American journal of Alzheimer's disease and other dementias · 2013Review
- Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer's disease: a review of clinical trials.TheScientificWorldJournal · 2013Review
- Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy.Alzheimer's research & therapy · 2013Article
- Influence of rs1080985 single nucleotide polymorphism of the CYP2D6 gene on response to treatment with donepezil in patients with alzheimer's disease.Neuropsychiatric disease and treatment · 2013Article
- Differential pharmacological effects on brain reactivity and plasticity in Alzheimer's disease.Frontiers in psychiatry · 2013Article
- Management of patients with Alzheimer's disease: pharmacological treatment and quality of life.Therapeutic advances in chronic disease · 2012Article
- Tau-targeted treatment strategies in Alzheimer's disease.British journal of pharmacology · 2012Review
- Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias.Dementia and geriatric cognitive disorders extra · 2012Article
- Recommended measures for the assessment of cognitive and physical performance in older patients with dementia: a systematic review.Dementia and geriatric cognitive disorders extra · 2012Article
- Article
- Nonmedical treatment of patients with dementia.Innovations in clinical neuroscience · 2011Article
- Drug treatment for people with dementia.Clinical medicine (London, England) · 2011Review
- Implications of the Impact Survey for payors across Europe.The journal of nutrition, health & aging · 2010Article
- Assessing physician attitudes and perceptions of Alzheimer's disease across Europe.The journal of nutrition, health & aging · 2010Article
- Good rate of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease after three months of treatment: An open-label study.Dementia & neuropsychologiaArticle
- Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver Outcomes.Dementia and geriatric cognitive disorders extraArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 4 countries.
Funding
Abstract
backgroundTherapeutic endpoints based on reduced clinical worsening represent clinically relevant and realistic goals for patients suffering from progressive neurodegenerative disorders such as Alzheimer's disease (AD).
methodsData from 906 patients (388 receiving placebo; 518 receiving donepezil) with mild-to-moderate AD [Mini-Mental State Examination (MMSE) score 10-27] were pooled from 3 randomized, double-blind placebo-controlled studies. Clinical worsening was defined as decline in (1) cognition (MMSE), (2) cognition and global ratings (Clinician's Interview-Based Impression of Change plus Caregiver Input/Gottfries-Bråne-Steen scale) or (3) cognition, global ratings and function (various functional measures).
resultsAt week 24, lower percentages of donepezil-treated patients than placebo patients met the criteria for clinical worsening, regardless of the definition. The odds of declining were significantly reduced for donepezil-treated versus placebo patients (p < 0.0001; all definitions). Among patients meeting criteria for clinical worsening, mean declines in MMSE scores were greater for placebo than donepezil-treated patients.
conclusionIn this population, donepezil treatment was associated with reduced odds of clinical worsening of AD symptoms. Moreover, patients worsening on donepezil were likely to experience less cognitive decline than expected if left untreated. This suggests that AD patients showing clinical worsening on donepezil may still derive benefits compared with placebo/untreated patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.